AMLX — AMYLYX PHARMACEUTICALS INC

Ownership history in Maven Securities LTD  ·  5 quarters on record

This page tracks every 13F SEC filing in which Maven Securities LTD reported a position in AMYLYX PHARMACEUTICALS INC (AMLX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.13% (2022 Q4)
Avg. % of fund
0.04%
First filed
2022 Q4
Last filed
2025 Q3
Quarters held
5
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 70,000 -30,000 -30.0% 0.02% $951K $13.59
2024 Q2 ADDED 100,000 +75,000 +300.0% 0.01% $190K $1.90
2024 Q1 REDUCED 25,000 -75,000 -75.0% 0.00% $71K $2.84
2023 Q1 REDUCED 100,000 -50,000 -33.3% 0.06% $2.9M $29.34
2022 Q4 INITIATED 150,000 — — 0.13% $5.5M —
% of Fund (quarterly)    AMLX price (monthly, adj. close)

Other funds also holding AMLX

As of 2025 Q4 — sorted by position size

Saturn V Capital Management LP 3Y 9.97% GREAT POINT PARTNERS LLC 3Y 7Y 6.85% Almitas Capital LLC 3Y 7Y 5.65% Commodore Capital LP 3Y 4.54% First Light Asset Management, LLC 3Y 7Y 3.1% ACUTA CAPITAL PARTNERS, LLC 3Y 7Y 2.73% TCG Crossover Management, LLC 3Y 2.5% Aldebaran Capital, LLC 3Y 2.15% PERCEPTIVE ADVISORS LLC 3Y 7Y 1.78% STEMPOINT CAPITAL LP 1.17%
← Back to Maven Securities LTD Holdings